mRNA Vaccines Boost Survival in Cancer Patients: Surprising Findings from Recent Study

In groundbreaking new research, it has been observed that cancer patients receiving mRNA-based COVID vaccines demonstrated significantly improved survival rates. Among 180 patients with advanced non-small cell lung cancer, those who received vaccines from Moderna or Pfizer/BioNTech had a median survival of 37.33 months, compared to 20.6 months for unvaccinated patients. The findings were presented at the 2025 European Society for Medical Oncology Congress in Berlin.

The study also highlighted the potential of vaccines in enhancing the effectiveness of immunotherapies. Dr. Adam Grippin from MD Anderson Cancer Center emphasized the affordability and accessibility of vaccines in improving patient outcomes, even for those with treatment-resistant conditions. The research was conducted amidst continuing debates on vaccine efficacy led by U.S. Health Secretary Robert F. Kennedy Jr.

In another study, a retinal implant developed by Science Corp showed promising results in reversing age-related macular degeneration, allowing legally blind patients to regain central vision. This device, demonstrated at the American Academy of Ophthalmology meeting, showed an average improvement of 25 letters on an eye chart. Both studies underscore the transformative potential of medical technology.